Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma

Figure 4

PCB-209 xenograft-derived in vivo trial results. Mean tumor volume of all treatment cohorts of the Jackson Lab-based PCB-209 patient-derived xenograft (PDX) model in vivo preclinical studies. (a) Tumor growth of crizotinib-treated PDX mice (n = 6) versus control (n = 4). (b) Tumor growth of carfilzomib-treated PDX mice (n = 7) versus control (n = 4). (c) Tumor growth of panobinostat-treated PDX mice (n = 8) versus control (n = 4). (d) Tumor growth of celecoxib- (n = 5), trametinib- (n = 5), and celecoxib + trametinib-treated (n = 4) PDX mice versus control (n = 4). (e) Tumor growth of ABT-737 (n = 7), midostaurin (n = 8), and ABT-737 + midostaurin-treated PDX mice (n = 2) versus control (n = 4). The p value was calculated without the midostaurin + ABT-737 due to low sample population, noted by the asterisk. The low number of models for the combination experiment is due to microbiological considerations at the Jackson Laboratory. In (a–e), the endpoint was treatment days 30–32.

(a)

(b)

(c)

(d)

(e)